<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41210" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Morvan Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Masood</surname>
            <given-names>Wajeed</given-names>
          </name>
          <aff>Methodist University, Campbell University School of Osteopathic Medicine.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lui</surname>
            <given-names>Forshing</given-names>
          </name>
          <aff>CA Northstate Uni, College of Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sitammagari</surname>
            <given-names>Kranthi K.</given-names>
          </name>
          <aff>Methodist Un, Campbell Un School of OM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Wajeed Masood declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Forshing Lui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kranthi Sitammagari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41210.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Morvan Syndrome is an uncommon and complex neurological disorder characterized by hyperactivity of the central, autonomic, and peripheral nervous systems. The disorder manifests in the central nervous system through symptoms such as confusion, behavioral changes, myoclonus, and insomnia, with additional occurrences of hallucinosis and encephalopathy. Autonomic hyperactivity includes features like hyperhidrosis, constipation, labile blood pressure, hemodynamic instability, and cardiac arrhythmias. Painful muscle cramps, myokymia, and neuromyotonia demonstrate peripheral nervous system hyperactivity.&#x000a0;</p>
        <p>Autoantibodies against proteins comprising the voltage-gated potassium channel complex (VGKC), specifically CASPR2 and LGI1, are often associated with Morvan syndrome. With&#x000a0;only 60 case reports published in French and even fewer in the English-language medical literature, Morvan syndrome poses diagnostic and treatment challenges to medical professionals. This educational activity for healthcare professionals aims to enhance their competence in managing Morvan syndrome. Clinicians completing the activity can expect improved diagnostic and treatment skills, ultimately leading to heightened proficiency in addressing the unique challenges associated with this rare and complex neurological condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the signs and symptoms&#x000a0;of Morvan syndrome.</p></list-item><list-item><p>Interpret antibody testing results and plan treatment accordingly.</p></list-item><list-item><p>Select a treatment modality that best suits the clinical presentation of Morvan syndrome.</p></list-item><list-item><p>Collaborate with the interprofessional team to recognize, diagnose, educate, treat, and monitor patients with Morvan syndrome to improve clinical outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41210&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41210">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41210.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Morvan syndrome (MoS) is a rare and complex disorder of nervous system hyperexcitability. Dr. Augustine Marie Morvan, a French physician, first described MoS in April 1890 in&#x000a0;<italic toggle="yes">La Gazette Hebdomadaire de Medecine et de Chirurgie</italic>. Morvan dubbed the syndrome <italic toggle="yes">la chor&#x000e9;e fibrillaire</italic> (fibrillary chorea), but we now know the disorder eponymously as Morvan syndrome.<xref ref-type="bibr" rid="article-41210.r1">[1]</xref><xref ref-type="bibr" rid="article-41210.r2">[2]</xref></p>
        <p>In the central nervous system, hyperexcitability manifests via confusion, behavioral changes, myoclonus, and severe insomnia; hallucinosis and encephalopathy may also occur. Autonomic hyperactivity includes hyperhidrosis, constipation, labile blood pressure, hemodynamic instability, and cardiac arrhythmias. Finally, peripheral nervous system hyperexcitability is typically demonstrated by painful muscle cramps, myokymia (vermicular or continuous rippling movements, often encountered as eyelid twitching), and neuromyotonia (involuntary continuous muscle fiber activity, often seen as fasciculations, doublet and triplet discharges on electromyography).<xref ref-type="bibr" rid="article-41210.r3">[3]</xref> In short, MoS combines peripheral and central nervous system hyperexcitable states; myokymia, neuromyotonia, muscle fasciculations, stiffness, autonomic nervous dysfunction, severe insomnia, and encephalopathy are commonly encountered, though most patients manifest only some of the symptoms that may occur.</p>
        <p>Until the mid-1950s, etiologic theories in MoS focused on infectious causes, especially viral infections; for the second half of the 20th&#x02013;century, etiologic theories focused on heavy metal toxicity. In 1999, the first report identified a new autoantibody member of the neurexin superfamily, an axonal transmembrane protein called anti-contactin-associated protein-like 2 (CASPR2). To date, approximately 60 case reports of CASPR2-associated MoS have been published in the French literature; the English language peer-reviewed medical literature boasts two case series numbering 43 patients in total.<xref ref-type="bibr" rid="article-41210.r4">[4]</xref><xref ref-type="bibr" rid="article-41210.r5">[5]</xref></p>
        <p>MoS is frequently paraneoplastic and is associated with malignant thymomas, in particular.<xref ref-type="bibr" rid="article-41210.r6">[6]</xref>&#x000a0;It is essential to distinguish MoS from acquired neuromyotonia and limbic encephalitis. MoS can be fatal in as many as a third of cases, although a recent small case series from the Indian subcontinent reported death as an outcome in only 1 of 8 patients.<xref ref-type="bibr" rid="article-41210.r7">[7]</xref></p>
        <p>A diagnosis of MoS is confirmed when serum antibody titers for CASPR2 and LGI1 are elevated. Therapeutic plasma exchange, often with immunosuppression, is the preferred treatment modality. Outcomes range from complete recovery to death, with the latter occurring in 20% of patients in a 2012 case series reported by Irani et al.<xref ref-type="bibr" rid="article-41210.r4">[4]</xref></p>
        <p>Consensus in the peer-reviewed medical literature supports the efficacy of immunomodulatory treatment, especially plasmapheresis, in MoS.<xref ref-type="bibr" rid="article-41210.r8">[8]</xref><xref ref-type="bibr" rid="article-41210.r9">[9]</xref><xref ref-type="bibr" rid="article-41210.r4">[4]</xref></p>
        <p>Little is known about the epidemiology of MoS, which is often unrecognized and thus unreported. Orphanet (accessed January 2024) reports the disease prevalence of MoS as less than one case per million. Consensus in the medical literature reveals MoS to be a strikingly male-dominated entity, with male-to-female ratios as high as 19:1 in some studies&#x000a0;<xref ref-type="bibr" rid="article-41210.r4">[4]</xref>&#x000a0;and ranging from 70% to 90% in others.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref></p>
      </sec>
      <sec id="article-41210.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Though it was first described in the late 19th&#x000a0;century, advances in the etiologic understanding of MoS have developed only since the late 1990s. MoS is an autoimmune neurological disorder belonging to the spectrum of conditions associated with antibodies to proteins constituting the voltage-gated potassium channel (VGKC) complex. VGKC antibodies contribute to the pathogenesis of MoS, acquired neuromyotonia (Isaac syndrome), limbic encephalitis, and faciobrachial dystonic seizures.<xref ref-type="bibr" rid="article-41210.r10">[10]</xref><xref ref-type="bibr" rid="article-41210.r4">[4]</xref>&#x000a0;</p>
        <p>In the first half of the 20<sup>th</sup> century, MoS was believed to occur as a sequela of viral infection.<xref ref-type="bibr" rid="article-41210.r11">[11]</xref><xref ref-type="bibr" rid="article-41210.r12">[12]</xref><bold>&#x000a0;</bold>Later, theories of association with heavy metal exposure were posited.<xref ref-type="bibr" rid="article-41210.r13">[13]</xref>&#x000a0;Recently, MoS occurring after Siddha traditional medicine treatment in India has been reported.<xref ref-type="bibr" rid="article-41210.r14">[14]</xref></p>
        <p>Since the late 1990s, MoS has been recognized for its strong association with Caspr2 autoantibodies. In some cases, antibodies to the leucine-rich glioma inactivated 1 (<italic toggle="yes">LgI1</italic>) protein (receptor subunits known as epitempin and DCC) and to the netrin-1 receptor have been identified as additional contributors to pathogenesis in MoS and limbic encephalitis.<xref ref-type="bibr" rid="article-41210.r15">[15]</xref><bold>&#x000a0;</bold>Netrin-1 has been implicated in angiogenesis, inflammation, tissue remodeling, and cancer:&#x000a0;antibodies to the netrin-1 receptor are associated with neuromyotonia in MG patients with previous thymomas.<xref ref-type="bibr" rid="article-41210.r15">[15]</xref><bold>&#x000a0;</bold>Finally, some patients have antibodies directed against the third identified antigenic component of the VGKC complex, contactin-2.<xref ref-type="bibr" rid="article-41210.r16">[16]</xref></p>
        <p>MoS has long been recognized as a paraneoplastic syndrome, most commonly associated with an underlying thymoma; cases of MoS concomitant with myasthenia gravis associated with underlying thymoma have been reported.<xref ref-type="bibr" rid="article-41210.r4">[4]</xref>&#x000a0;Cancers of the lung, sigmoid colon, and testicles and hematologic malignancies, such as lymphoma, can also occur. It should be noted, however, that MoS can occur without underlying cancer; in such cases, the response to immunotherapy may be better than in paraneoplastic cases.<xref ref-type="bibr" rid="article-41210.r17">[17]</xref></p>
        <p>One report has shown CASPR2 protein-coding mRNA in the prostate gland, supporting the possibility that the male reproductive system may harbor these antigens besides brain tissue. This finding was consistent with the onset of MoS&#x000a0;in a few patients after scrotal drainage, as reported by Irani et al.<xref ref-type="bibr" rid="article-41210.r18">[18]</xref><xref ref-type="bibr" rid="article-41210.r19">[19]</xref>. Isolated case reports have implicated mRNA vaccinations against COVID-19 as causing a case of LGI1 Limbic encephalitis.<xref ref-type="bibr" rid="article-41210.r20">[20]</xref></p>
      </sec>
      <sec id="article-41210.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The true epidemiology of MoS is unknown; systematic patient series are few, and, as a result, the condition is likely significantly underrecognized and, therefore, underreported.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref>&#x000a0; One case series in 2012 reported information about 29 patients;<xref ref-type="bibr" rid="article-41210.r22">[22]</xref> a 2021 case series reported data from an additional 14 cases.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref></p>
        <p>According to Orphanet (accessed January 2024), MoS is a rare&#x02014;less than 1 case per million&#x02014;and life-threatening acquired neurologic disease characterized by neuromyotonia, dysautonomia, and encephalopathy, with severe insomnia.&#x000a0;</p>
        <p>MoS has an overwhelming male predominance. Murine models&#x000a0;in utero exposure to endogenous maternal polyclonal CASPR2 antibodies demonstrated abnormal cortical development in male offspring only.<xref ref-type="bibr" rid="article-41210.r23">[23]</xref>&#x000a0;Quite recently, a case report about a woman with multiple positive antibodies, including LGI1, was reported.<xref ref-type="bibr" rid="article-41210.r24">[24]</xref></p>
        <p>As mentioned, MoS is often a paraneoplastic disorder. Paraneoplastic disorders&#x000a0;frequently go underdiagnosed and underreported, even though paraneoplastic disease develops in 1 out of 300 patients with cancer; paraneoplastic incidence is estimated to lie between 1.6 and 8.9 cases per million person-years.<xref ref-type="bibr" rid="article-41210.r6">[6]</xref></p>
        <p>In MoS, 75% of cases reportedly demonstrate positivity to Caspr2 antibodies, 60% to LGI1 antibodies, and lower percentages reveal antibodies to netrin-1 or acetylcholine receptors; thymoma is present in 50% to 90% of cases.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref></p>
      </sec>
      <sec id="article-41210.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>As previously noted, antibodies against&#x000a0;2 VGKC complex proteins, CASPR2 and LGI1, are now strongly implicated in the pathogenesis of MoS.<xref ref-type="bibr" rid="article-41210.r25">[25]</xref><xref ref-type="bibr" rid="article-41210.r4">[4]</xref>&#x000a0;CASPR2 is expressed predominantly in the peripheral nervous system, whereas LGI1 is found in the central and peripheral nervous systems. There is experimental evidence that these antibodies cause neuronal hyperexcitability by suppressing voltage-gated potassium outward currents needed for the repolarization of the motor nerve. Immunostaining of brain tissue shows that these antibodies target subtly different neural substrates likely to underlie the distinctive clinical features seen in Morvan syndrome.</p>
        <p>MoS encompasses a wide variety of clinical presentations. LGI1 antibody-mediated autoimmune disorders present mainly with limbic encephalitis, hyponatremia, REM sleep behavioral disorders, and classic faciobrachial dystonic seizures. CASPR2 antibody syndromes&#x000a0;are characterized primarily by&#x000a0;peripheral nervous system hyperexcitability. MoS can present with any combination of these symptomatologies, depending on the presence of antibodies against CASPR2, LGI1, or both.<xref ref-type="bibr" rid="article-41210.r19">[19]</xref><xref ref-type="bibr" rid="article-41210.r26">[26]</xref><xref ref-type="bibr" rid="article-41210.r27">[27]</xref></p>
        <p>First described in 1999, CASPR2 is a neurexin superfamily transmembrane cell adhesion protein that regulates the recruitment of Kv1.1 and Kv1.2 VGKC subunits at the juxtaparanodal region of myelinated axons, important for proper electrical function.<xref ref-type="bibr" rid="article-41210.r28">[28]</xref><xref ref-type="bibr" rid="article-41210.r29">[29]</xref><xref ref-type="bibr" rid="article-41210.r21">[21]</xref>&#x000a0;An animal model recently demonstrated that CASPR2 antibodies can also alter CASPR2 function in the hippocampi, leading to reduced numbers of inhibitory neurons in the hippocampus and&#x000a0;suggesting that antibody activity in the brain parenchyma may contribute to hyperexcitability of both the peripheral and central nervous systems.<xref ref-type="bibr" rid="article-41210.r23">[23]</xref><xref ref-type="bibr" rid="article-41210.r30">[30]</xref></p>
        <p>LGI1 is a secreted cell surface protein complex expressed predominantly in the cornu ammonis (CA) 1 and 3 regions of the hippocampus and the dentate gyrus.<xref ref-type="bibr" rid="article-41210.r31">[31]</xref>&#x000a0;The leucine-rich repeat subunit is essential for LGI1/LGI1 dimerization, and an epitempin domain (EPTP) mediates the LGI1/ADAM22/23 interaction. The LGI1 protein is crucial for synaptic transmission through its orchestration of interactions with presynaptic K<sub>v</sub>1.1 channels and the postsynaptic &#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptor (AMPA-R).<xref ref-type="bibr" rid="article-41210.r8">[8]</xref><xref ref-type="bibr" rid="article-41210.r9">[9]</xref><xref ref-type="bibr" rid="article-41210.r10">[10]</xref><bold>&#x000a0;</bold>In one recently reported paper, serum from LGI1 patients with autoimmune encephalitis produced reduced AMPA-R density and caused interruptions in the hippocampal LGI1-ADAM22/23 interaction, collectively leading to modified synaptic transmission.<xref ref-type="bibr" rid="article-41210.r32">[32]</xref></p>
        <p>The various combinations of LGI1 and CASPR2 antibody binding likely contribute to the distinctive and complex phenotypes encountered in MoS.&#x000a0;Monoaminergic nuclei in the diencephalon and brain stem are known to be involved in arousal and autonomic homeostasis. A disturbance in this homeostasis can cause insomnia, dysautonomia, and, less frequently, hyponatremia.&#x000a0;Dysfunction in the neurons anywhere in the thalamus, hypothalamus, locus coeruleus, and raphe nuclei produces insomnia.&#x000a0;The dysautonomia noted in MoS&#x000a0;is likely generated within the hypothalamus and raphe nuclei. SIADH-related hyponatremia has been found in patients with LGI1 antibodies:<bold>&#x000a0;</bold>the LGI1 antibody binds to hypothalamic neurons that produce the anti-diuretic hormone, and hyponatremia plausibly arises due to receptor-mediated increased secretion.<xref ref-type="bibr" rid="article-41210.r33">[33]</xref><xref ref-type="bibr" rid="article-41210.r34">[34]</xref>Low plasma sodium is also occasionally associated with CASPR2 antibodies, though&#x000a0;the mechanism has yet to be elucidated.</p>
        <p>Of note, additional antibodies are occasionally found along with CASPR2 and LGI1 antibodies, including antibodies to the DCC and UNC5a receptors of the anti-Netrin-1 protein (especially in the presence of a thymoma) and antibodies against nonneuronal targets, such as antinuclear or antithyroid antibodies. The role of these additional antibodies in paraneoplastic pathogenesis remains unclear.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref></p>
        <p>As mentioned earlier (See Etiology), some MoS patients have anti-contactin-2 antibodies, rarely found in limbic encephalitis. Contactin-2 is expressed in cardiac conduction tissue, and some reports posit that anti-contactin-2 antibodies may prompt cardiovascular instability in MoS. Some patients display reactivity to antigenic targets inconsistent with LGI1, CASPR2, or contactin-2, leading to the suspicion that additional, not-yet-identified antibody reactivities are present in at least some patients with MoS. This is an area that is ripe for further research.<xref ref-type="bibr" rid="article-41210.r35">[35]</xref></p>
        <p>In paraneoplastic syndromes,&#x000a0;2 broad categories of autoantibodies are implicated. The first group comprises antibodies targeting intracellular nuclear or cytoplasmic antigens, such as anti-Hu, anti-Yo, and anti-Ri antibodies. These antibodies are not directly pathogenic in causing the clinical paraneoplastic syndrome. The second group comprises antibodies targeting cell-surface and synaptic antigens, such as anti-GABAa and anti-NMDA antibody syndromes. These antibodies are pathogenic, causing a B-cell-mediated response at the target antigens.<xref ref-type="bibr" rid="article-41210.r36">[36]</xref>&#x000a0;VGKC is a cell-surface or synaptic protein complex that includes CASPR2 and LGI1. The antibodies targeting these proteins are understood to be directly pathogenic through B-cell-mediated pathogenic mechanisms. Treatments targeting the autoantibodies and B-cells are expected to be beneficial.</p>
        <p>Regarding insomnia, MoS represents functional interruptions in thalamolimbic circuits regulating the sleep-wake cycle and control of the autonomic system. Thalamic degeneration in MoS may be reversible, distinguishing MoS from fatal familial insomnia, a human prion disease characterized by selective severe atrophy of thalamic mediodorsal and anteroventral nuclei with disconnection of the limbic cortical areas and subcortical regions.<xref ref-type="bibr" rid="article-41210.r37">[37]</xref><xref ref-type="bibr" rid="article-41210.r3">[3]</xref></p>
        <p>Thymectomy and thymoma chemotherapy may trigger the onset of MoS, supporting the possibility that thymic tumors shelter antigenic targets, particularly CASPR2, and somehow become exposed and potentially vulnerable to antibody attack following thymectomy or thymoma chemotherapy.&#x000a0;</p>
      </sec>
      <sec id="article-41210.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>MoS is characterized by central, autonomic, and peripheral nervous system hyperactivity.<xref ref-type="bibr" rid="article-41210.r38">[38]</xref><xref ref-type="bibr" rid="article-41210.r1">[1]</xref><xref ref-type="bibr" rid="article-41210.r39">[39]</xref>. Historically, findings of neuropsychological dysfunction, autonomic dysfunction, and disordered sleep have been underrepresented in clinical characterizations of MoS, underscoring the need to collect the maximum amount of relevant data when assessing a patient for the possibility of MoS.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref>&#x000a0;</p>
        <p>CNS features of MoS include encephalopathy, severe insomnia, vivid (usually auditory)&#x000a0;hallucinations, delirium, spatial and temporal disorientation, confusion, amnesia, agitation, and hostility. Dysautonomia is primarily characterized by instability, and features include excessive sweating, fever, palmoplantar erythema, pruritus, drooling, severe constipation, excessive lacrimation, arrhythmias, hypertension, weight loss, skin and, rarely, hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion.<xref ref-type="bibr" rid="article-41210.r1">[1]</xref><xref ref-type="bibr" rid="article-41210.r40">[40]</xref> The peripheral nervous system (PNS) features include peripheral nerve hyperexcitability resulting in continuous muscle fiber activity, neuropathic pain, areflexia (loss of deep tendon reflexes), and a stocking-type sensory loss. Continuous muscle fiber activity is manifested as neuromyotonia, which is clinically seen as myokymia.<xref ref-type="bibr" rid="article-41210.r41">[41]</xref><xref ref-type="bibr" rid="article-41210.r42">[42]</xref><xref ref-type="bibr" rid="article-41210.r43">[43]</xref></p>
        <p>Variable occurrence of the clinical features of MoS is well known and usually depends on the type of antibody detected, whether anti-CASPR2, anti-LGI1, antibodies to both CASPR2 and LGI1, or a combination of other antibodies. Despite the preponderance of peripheral nervous system dysfunction associated with reactivity to CASPR2, MoS patients also frequently present with limbic symptoms at onset, more often seizures than cognitive dysfunction, and most have limbic involvement at some point during their clinical course. Cerebellar ataxia is also common in this population.<xref ref-type="bibr" rid="article-41210.r44">[44]</xref>&#x000a0;Serum hyponatremia, delusions, and myoclonus are more common in the presence of LGI1 antibodies.</p>
        <p>History-taking in possible MoS should focus on defining the constellation of specific symptoms with which a given individual patient presents clinically. Particularly useful lines of questioning would be those focusing on the topics listed below.</p>
        <p><bold>Family history:&#x000a0;</bold>A hereditary origin of neuromuscular hyperexcitability should always be ruled out, even in non-VGKC-related genes, as evidenced by the recently discovered high frequency of mutations in people of Slavic origin. Peripheral nervous system hyperexcitability has also variably been associated with abnormalities in the <italic toggle="yes">KCNA1, KCNQ2, CAV3</italic>, and <italic toggle="yes">HSPG2</italic> genes.<xref ref-type="bibr" rid="article-41210.r45">[45]</xref><bold>&#x000a0;</bold></p>
        <p><bold>Comorbid conditions:&#x000a0;</bold>Practitioners should specifically inquire about concomitant autoimmune diseases, such as myasthenia gravis, thyroiditis, systemic lupus erythematosus, or autoimmune cytopenia.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref>&#x000a0;A thorough history of neoplasm, especially&#x000a0;cancers of the lung, sigmoid colon, and testicles, along with hematologic malignancies, such as lymphoma, should be obtained.&#x000a0;</p>
        <p><bold>Signs of peripheral or central nervous system hyperexcitability:&#x000a0;</bold>Salient signs of nervous system hyperexcitability include history of seizures (especially the typical ictus of faciobrachial dystonic seizures, with brief, posturing movements of the hand and ipsilateral hemiface),<xref ref-type="bibr" rid="article-41210.r46">[46]</xref>&#x000a0;stereotypical movements (eg, wringing of the hands), neuropathic pain, stocking-glove sensory dysfunction, falls or ataxia, twitching (myoclonus), and muscle cramps.</p>
        <p><bold>Signs of dysautonomia:&#x000a0;</bold>Dysautonomia may appear in a plethora of ways, including recent constipation, hyperhidrosis, sialorrhea, polydipsia, weight loss, diffuse itching, lacrimation, cardiac arrhythmias, and hypertension.</p>
        <p><bold>Behavior and comportment:&#x000a0;</bold>Delusions or hallucinations, confusion, temporal disorientation, memory or other cognitive problems, agitation, irritability, and hostility may reveal encephalopathy.<xref ref-type="bibr" rid="article-41210.r3">[3]</xref></p>
        <p><bold>Sleep history:&#x000a0;</bold>Insomnia may be severe and is often characterized by dream enactment behavior, periodic limb movements, and REM sleep without atonia. Insomnia in patients with CASPR2 antibodies is often characterized by agrypnia excitata, a rare syndrome of near-total absence of sleep accompanied by hyperactivation of the central and autonomic nervous systems; agrypnia excitata is found only in MoS, delirium tremens, and the prion disease known as fatal familial insomnia.<xref ref-type="bibr" rid="article-41210.r46">[46]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-41210.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The detection of VGKC antibodies in serum is diagnostic of MoS. Although these antibodies are directed against CASPR2&#x000a0;and LGI1 (more commonly both), the CASPR2 antibody is particularly associated with malignant thymoma. Current practice recommendations suggest obtaining serum antibody testing only for CASPR2 and LGI1 instead of more global VGKC antibody testing, as low levels of VGKC abnormalities are commonly found in healthy controls.<xref ref-type="bibr" rid="article-41210.r47">[47]</xref> In MoS, CASPR2 antibodies are found in serum rather than cerebrospinal fluid; antibody titers in MoS tend to be lower than in autoimmune limbic encephalitis patients.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref>&#x000a0;</p>
        <p>Therefore, the multidimensional clinical presentation possible in MoS necessitates the ability to recognize the syndrome with a high index of clinical suspicion. The investigations that would typically be performed in cases of nervous system hyperexcitability&#x02014;such as cerebrospinal fluid analysis, magnetic resonance imaging of the brain, electroencephalography (EEG), and positron emission scans&#x02014;may yield little diagnostic help; these investigations have their greatest utility in ruling out other diagnostic possibilities. Some studies are helpful in seeking associated underlying malignancies. Electromyography (EMG) can confirm myokymia. However,&#x000a0;EMG in MoS typically shows fasciculations, multiplets, and after-discharges; myokymia and neuromyotonia are rarely seen in electrodiagnostic studies.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref></p>
        <p>The evaluation, in summary, is a two-step approach. The first step is confirmation by detecting the autoantibodies in the serum or the CSF. The second step is to look for underlying cancer by imaging such as CT chest, abdomen, pelvis, or PET scan.</p>
        <p>Diagnostic workup should include a search for possibly associated autoimmune diseases, such as myasthenia gravis (ie, elevated levels of acetylcholine receptor antibodies and abnormal decrement after repetitive nerve stimulation on EMG) or autoimmune cytopenia.&#x000a0;When antibody testing is&#x000a0;positive for elevated titers of CAPSR2 or LGI1, a workup for occult malignancy is imperative; ruling out malignant thymoma in patients with CASPR2 antibodies is particularly important.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref></p>
        <p>To evaluate dysautonomia &#x0201c;at the bedside,&#x0201d; tests of orthostasis, heart rate changes with deep breathing, and the Valsalva maneuver should be performed.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref></p>
        <p>Polysomnography (PSG) is often thwarted by a patient&#x02019;s inability to fall asleep and, in some cases, even to cooperate with the study due to behavioral abnormalities and encephalopathy.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref> PSG results in patients with MoS have documented reduced or absent sleep spindles and K complexes (typical features of stage 2 NREM sleep), REM sleep without atonia, and absent or severely reduced slow-wave sleep. In many patients, sleep is so dysfunctional as to satisfy criteria for agrypnia excitata.<xref ref-type="bibr" rid="article-41210.r48">[48]</xref></p>
        <p>Spot EEG is often normal or otherwise unrevealing. However, a 2022 case series exploring the frequency of seizures after the&#x000a0;putative achievement of seizure freedom in autoimmune encephalitis due to CASPR2 or LGI1 antibodies has questioned the consensus regarding favorable seizure outcomes in this population. The investigators posited that the incidence of persistent seizures may be as high as 20%. Prolonged video-EEG telemetry is recommended in this patient population and could also be helpful in more straightforward presentations of MoS.<xref ref-type="bibr" rid="article-41210.r49">[49]</xref></p>
        <p>FDG-PET may be revealing in cases of LGI1 autoimmune encephalitis. In cases where the encephalitis is associated with CASPR2 antibodies, FDG-PET findings have yet to be studied conclusively. A preliminary study has reported that medial temporal hypermetabolism and diffuse cortical hypometabolism were found on visual inspection in CASPR2 encephalitis, even without standardized findings (e.g., visual and voxel-based methods). However, standardized PET image analysis, compared to databases of normal studies to clarify the areas with pathological metabolism, is not yet available.<xref ref-type="bibr" rid="article-41210.r3">[3]</xref>&#x000a0;FDG-PET can be positive even if structural brain imaging and EEG are negative.<xref ref-type="bibr" rid="article-41210.r50">[50]</xref></p>
        <p>Muscle biopsy may be useful to exclude myopathy or mitochondrial disease in patients with prominent peripheral symptoms.<xref ref-type="bibr" rid="article-41210.r50">[50]</xref></p>
      </sec>
      <sec id="article-41210.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Clinicians have tried several treatment modalities with variable clinical responses, including gold therapy, antiepileptic agents, such as carbamazepine, valproate, phenobarbital, and phenytoin, and procedures such as thymectomy, generally without significant success.</p>
        <p>Plasma exchange appears to be the most effective treatment available for MoS; immunosuppression with corticosteroids or other immunosuppressant agents is often also necessary.<xref ref-type="bibr" rid="article-41210.r1">[1]</xref> For reasons that remain unclear, the clinical response to plasma exchange&#x000a0;and immunosuppression is variable, possibly due to variability in the mixture of serum factors responsible for causing symptoms. Some authors postulate that immunosuppression is more effective when MoS is&#x000a0;associated with other autoimmune conditions, such as myasthenia gravis or autoimmune thyroid disorders. Case reports indicate that symptomatology refractory to plasma exchange may nonetheless respond to agents such as azathioprine, rituximab, and lacosamide.<xref ref-type="bibr" rid="article-41210.r51">[51]</xref><xref ref-type="bibr" rid="article-41210.r52">[52]</xref>&#x000a0;Removal of CASPR2 and LGI1 antibodies may also improve agrypnia excitata (even when accompanied by oneiric stupor), though the overall prognosis remains poor in such cases.<xref ref-type="bibr" rid="article-41210.r37">[37]</xref></p>
        <p>A recent Japanese case report underscored the clinicopathological relationship between an unresectable malignant thymoma and MoS, noting that chemotherapy directed against the thymoma both shrank the lesion and improved the symptoms of MoS, suggesting a strong clinical correlation between thymoma and MoS disease activity and raising the tantalizing possibility (not yet investigated) that chemotherapy for thymoma might have utility as a treatment for MoS.<xref ref-type="bibr" rid="article-41210.r53">[53]</xref></p>
      </sec>
      <sec id="article-41210.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Documented diagnostic misadventures in MoS have included overinterpretation of positive serum antibodies and mistaking functional, psychiatric, or nonspecific cognitive symptoms for encephalopathy.<xref ref-type="bibr" rid="article-41210.r54">[54]</xref><xref ref-type="bibr" rid="article-41210.r55">[55]</xref></p>
        <p>Limbic encephalitis<xref ref-type="bibr" rid="article-41210.r40">[40]</xref>&#x000a0;caused by autoantibodies other than CASPR2 or LGI1 has remarkably similar CNS features to MoS despite subtle differences between these&#x000a0;2 conditions. In limbic encephalitis, amnesia, seizures, and structural abnormalities of the temporal lobe on imaging occur more prominently, but each symptom can also occur in MoS. In limbic encephalitis, neuromyotonia and dysautonomia are generally conspicuous by their absence. Co-occurrence of limbic encephalitis and neuromyotonia is insufficient to warrant a diagnosis of MoS.<xref ref-type="bibr" rid="article-41210.r56">[56]</xref> Additional features that can help distinguish MoS from classical limbic encephalitis are neuropathic lower limb pain, weight loss, male sex, and association with malignant thymomas.</p>
        <p>Acquired neuromyotonia, eponymously known as Isaac syndrome,<xref ref-type="bibr" rid="article-41210.r57">[57]</xref>&#x000a0;overlaps with&#x000a0;MoS in terms of peripheral nerve hyperexcitability, but in Isaac syndrome, overt central or autonomic nervous dysfunction is absent. MoS patients often present with marked weight loss and asthenia features normally absent in Isaacs syndrome.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref> It is important to distinguish peripheral nerve hyperexcitability syndromes from stiff person syndrome, myotonic disorders, and rippling muscle disease.<xref ref-type="bibr" rid="article-41210.r58">[58]</xref><xref ref-type="bibr" rid="article-41210.r59">[59]</xref>&#x000a0;Myokymia can be a presenting feature of multiple sclerosis<xref ref-type="bibr" rid="article-41210.r60">[60]</xref> and cervical radiculopathy,<xref ref-type="bibr" rid="article-41210.r61">[61]</xref> and it has occurred as an adverse effect of medications such as gabapentin and acetazolamide.<xref ref-type="bibr" rid="article-41210.r62">[62]</xref><xref ref-type="bibr" rid="article-41210.r63">[63]</xref></p>
        <p>Guillain-Barre syndrome (GBS)<xref ref-type="bibr" rid="article-41210.r39">[39]</xref>&#x000a0;is an immune system-mediated ascending neuropathy with muscle weakness, loss of deep tendon reflexes, and sensory deprivation resulting from damage to the peripheral nervous system. A viral infection usually triggers GBS; less commonly, it can present after surgery or vaccination. Diagnosis is generally through clinical exclusion and supported by tests such as nerve conduction studies and CSF analysis. In severe cases, prompt treatment with intravenous immunoglobulins or plasmapheresis and supportive care will lead to functional recovery in the majority.</p>
        <p>For comprehensiveness, one ought to include fatal familial insomnia in the differential diagnosis for MoS, as the two conditions overlap in terms of the presence of agrypnia excitata.<xref ref-type="bibr" rid="article-41210.r64">[64]</xref><xref ref-type="bibr" rid="article-41210.r65">[65]</xref>&#x000a0;However, FFI is a prion disease, and structural brain abnormalities are usually obvious on MRI imaging, unlike MoS.</p>
      </sec>
      <sec id="article-41210.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Recently, a randomized placebo-controlled clinical trial demonstrated the superiority of intravenous immunoglobulin to placebo in autoimmune epilepsy occurring secondary to positive titers of CASPR2 and LGI1.<xref ref-type="bibr" rid="article-41210.r66">[66]</xref></p>
        <p>Some patients display reactivity to antigenic targets inconsistent with LGI1, CASPR2, or contactin-2, leading to the suspicion that additional, not-yet-identified antibody reactivities are present in at least some patients with MoS. This is an area that is ripe for further research.<xref ref-type="bibr" rid="article-41210.r35">[35]</xref></p>
      </sec>
      <sec id="article-41210.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The natural history of Morvan syndrome is surprisingly variable, ranging from complete recovery to death. Some cases have been reported to remit spontaneously, and many patients require extensive treatment, mainly in the form of immunotherapy in the form of plasma exchange and long-term immunosuppression.&#x000a0;Some cases were fatal; 20% of MoS patients in the 2012 case series by Irani et al died.<xref ref-type="bibr" rid="article-41210.r4">[4]</xref> MoS is a life-threatening condition due to severe dysautonomia and its frequent association with malignant thymoma.<xref ref-type="bibr" rid="article-41210.r21">[21]</xref></p>
      </sec>
      <sec id="article-41210.s12" sec-type="Complications">
        <title>Complications</title>
        <p>As noted previously, obtaining PSG is often challenging in MoS, as patients may experience little or no sleep and, in some cases, even be unable to cooperate with the study due to behavioral abnormalities and encephalopathy.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref></p>
        <p>Under anesthesia, spontaneous laryngeal spasms secondary to neuromyotonia and hyperexcitability secondary to potassium channel dysfunction have been reported. To minimize the possibility of laryngospasm, local or regional anesthetic agents are preferred over general anesthesia; muscle-relaxing agents should be avoided to the extent possible.<xref ref-type="bibr" rid="article-41210.r67">[67]</xref></p>
      </sec>
      <sec id="article-41210.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients suspected to have Morvan syndrome, due to its extensive neurological symptomatology, would benefit from a neurology consultation in all cases, especially with neurologists specialized in neuroimmunology, neuromuscular disorders, and dysautonomia. Depending on other clinical complications such as cardiac arrhythmias, either cardiology or possibly electrophysiology consultation would be pertinent. The high prevalence of occult malignancies in MoS necessitates the early involvement of oncology. Involving physical, occupational, and speech therapists may help decrease caregiver burden.&#x000a0;</p>
      </sec>
      <sec id="article-41210.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about the rarity of Morvan syndrome, the conditions it mimics or with which it can be confused, and its association with occult malignancies. Patients should also be informed that MoS is often responsive to treatment, and full recovery occurs in some patients.</p>
        <p>MoS patients may need considerable support from unpaid caregivers. Extensive physical, occupational, and speech rehabilitation can ameliorate caregiver burden.<xref ref-type="bibr" rid="article-41210.r55">[55]</xref></p>
        <p>Patients should be cautioned about the risk of laryngospasm with general anesthesia and should be instructed to review their MoS with the anesthesiologist before any surgical or other procedure.</p>
      </sec>
      <sec id="article-41210.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Identification in the serum of either or both of the auto-antibodies, LGI1 and CASPR2, is the hallmark of the diagnosis of MoS, given the wide variety of clinical manifestations affecting the central and peripheral nervous systems. A high index of suspicion is vital.</p>
        <p>Recall that titers of CASPR2 usually exceed those of LGI1. CASPR2 positivity is particularly associated with malignant thymoma, which should be investigated in all cases.</p>
        <p>The remarkable clinical improvement often noted after plasma exchange strongly supports the idea that autoantibodies cause this condition. Although the combination of CASPR2 and LGI1 antibodies may explain many aspects of the clinical phenotype, antibody positivity alone offers an insufficient characterization of MoS. It is possible, even likely, that additional antibodies directed against other VGKC-complex proteins will be identified, leading to an improved understanding of the complex presentation with multifocal localization typically seen in MoS.</p>
        <p>The index patient in MoS presented with symptoms of irregular small muscle contractions, painful muscle cramps, itching, hyperhidrosis, delirium, hallucinations, and severe sleep disturbances.<xref ref-type="bibr" rid="article-41210.r3">[3]</xref></p>
      </sec>
      <sec id="article-41210.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinical consciousness-raising about the presentation and natural history of MoS is needed to prompt heightened awareness of the condition, facilitating early recognition that could lead to potentially curable immunotherapy.<xref ref-type="bibr" rid="article-41210.r5">[5]</xref></p>
        <p>Providing patient-centered care for individuals with MoS requires a collaborative effort among healthcare professionals, including physicians, advanced practice practitioners, nurses, pharmacists, therapists, and others. First and foremost, healthcare team members must possess the necessary clinical skills and expertise&#x000a0;when diagnosing, evaluating, and treating MoS. This includes proficiency in interpreting serum antibody titers, recognizing potential complications, and understanding the nuances of managing this multidimensional disease of overlapping nervous system hyperexcitability. Cardiology and oncology may require consultation depending on the array of symptoms displayed by a given patient with MoS.&#x000a0;Moreover, a strategic approach involving individualized care plans tailored to each patient's unique circumstances is vital. To date, no clinical practice guidelines inform the management of MoS, and resources for patient education are largely nonexistent.</p>
        <p>Ethical considerations come into play when determining treatment options and respecting patient autonomy in decision-making. Responsibilities within the interprofessional team should be clearly defined, with each member contributing their specialized knowledge and skills to optimize patient care. Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>Lastly, care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by MoS.</p>
      </sec>
      <sec id="article-41210.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41210&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41210">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/morvan-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=41210">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41210/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41210">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-41210.s18">
        <fig id="article-41210.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Morvan&#x000a0;Syndrome Table Contributed by Wajeed Masood MD, CHCQM-PHYADV</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_20180524_121450" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-41210.s19">
        <title>References</title>
        <ref id="article-41210.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Josephs</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fealey</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Nippoldt</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Auger</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Vernino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neurophysiologic studies in Morvan syndrome.</article-title>
            <source>J Clin Neurophysiol</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>440</fpage>
            <page-range>440-5</page-range>
            <pub-id pub-id-type="pmid">15622131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walusinski</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Augustin Morvan (1819-1897), a little-known rural physician and neurologist.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>169</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-8</page-range>
            <pub-id pub-id-type="pmid">22763207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suresh Kumar</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Sajithlal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shamsudeen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Morvan's syndrome Presenting with Psychiatric Manifestations - A Case Report and Review of the Literature.</article-title>
            <source>Neurol India</source>
            <year>2022</year>
            <season>May-Jun</season>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>1207</fpage>
            <page-range>1207-1209</page-range>
            <pub-id pub-id-type="pmid">35864667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pettingill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kleopa</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Schiza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zuliani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Morvan syndrome: clinical and serological observations in 29 cases.</article-title>
            <source>Ann Neurol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>241</fpage>
            <page-range>241-55</page-range>
            <pub-id pub-id-type="pmid">22473710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swayang</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Nalini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Preethish-Kumar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Udupa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vengalil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reshma</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Polavarapu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sathyaprabha</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Treesa Thomas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jamuna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahadevan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Netravathi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>CASPR2-Related Morvan Syndrome: Autonomic, Polysomnographic, and Neuropsychological Observations.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>e267</fpage>
            <page-range>e267-e276</page-range>
            <pub-id pub-id-type="pmid">34484901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramalho</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Abreu Fernandes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petrova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Morvan's Syndrome: The Importance of Knowing Different Risk-Associated Phenotypes and Antibodies in Identifying the Correct Underlying Tumor.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e33841</fpage>
            <pub-id pub-id-type="pmid">36819439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shivaram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagappa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seshagiri</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Mahadevan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gangadhar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sathyaprabha</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Kumavat</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bharath</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taly</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Clinical Profile and Treatment Response in Patients with CASPR2 Antibody-Associated Neurological Disease.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2021</year>
            <season>Mar-Apr</season>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-185</page-range>
            <pub-id pub-id-type="pmid">34220060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mallhi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Asthana</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kushwaha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Successful therapeutic plasma exchange in a patient with Morvan syndrome.</article-title>
            <source>Asian J Transfus Sci</source>
            <year>2019</year>
            <season>Jan-Jun</season>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-75</page-range>
            <pub-id pub-id-type="pmid">31360018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strasser</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Principles of Therapeutic Apheresis in Neurological Disease.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>88</fpage>
            <page-range>88-97</page-range>
            <pub-id pub-id-type="pmid">37066058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hart</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Maddison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Newsom-Davis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic variants of autoimmune peripheral nerve hyperexcitability.</article-title>
            <source>Brain</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>Pt 8</issue>
            <fpage>1887</fpage>
            <page-range>1887-95</page-range>
            <pub-id pub-id-type="pmid">12135978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaude</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gambhir</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Morvan's syndrome-is a pathogen behind the curtain?</article-title>
            <source>Neurol Sci</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>1965</fpage>
            <page-range>1965-1969</page-range>
            <pub-id pub-id-type="pmid">30090985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eikeland</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A Patient with Double-Negative VGKC, Peripheral Nerve Hyperexcitability, and Central Nervous System Symptoms: A Postinfectious Autoimmune Disease.</article-title>
            <source>Case Rep Neurol Med</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>3579419</fpage>
            <pub-id pub-id-type="pmid">32802532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>IJ</given-names>
              </name>
            </person-group>
            <article-title>Mercury-induced autoimmunity: Report of two adolescent siblings with Morvan syndrome "plus" and review of the literature.</article-title>
            <source>J Neuroimmunol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>22</day>
            <volume>342</volume>
            <fpage>577197</fpage>
            <pub-id pub-id-type="pmid">32126315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vijay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Saravanan</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Krishnasamy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Raju</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Morvan's Syndrome after Siddha Drug Intake.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>11</fpage>
            <page-range>11-12</page-range>
            <pub-id pub-id-type="pmid">37355802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gastaldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maestri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zardini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scaranzin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borrelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferraro</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Lampasona</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Furlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marchioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ricciardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Franciotta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study.</article-title>
            <source>Eur J Neurol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>992</fpage>
            <page-range>992-999</page-range>
            <pub-id pub-id-type="pmid">30714278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Renna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Plantone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jandolo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koudriavtseva</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report.</article-title>
            <source>Oncol Lett</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>2716</fpage>
            <page-range>2716-2719</page-range>
            <pub-id pub-id-type="pmid">27698847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binks</surname>
                <given-names>SNM</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2018</year>
            <month>May</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-534</page-range>
            <pub-id pub-id-type="pmid">29055902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic Spectrum of CASPR2 and LGI1 Antibodies Associated Neurological Disorders in Children.</article-title>
            <source>Front Pediatr</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>815976</fpage>
            <pub-id pub-id-type="pmid">35463890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kleopa</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Pettingill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zuliani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peles</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.</article-title>
            <source>Brain</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>133</volume>
            <issue>9</issue>
            <fpage>2734</fpage>
            <page-range>2734-48</page-range>
            <pub-id pub-id-type="pmid">20663977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zlotnik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gadoth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abu-Salameh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Novoa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ifergane</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>813487</fpage>
            <pub-id pub-id-type="pmid">35069602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comperat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pegat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joubert</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune neuromyotonia.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2022</year>
            <month>Oct</month>
            <day>01</day>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>597</fpage>
            <page-range>597-603</page-range>
            <pub-id pub-id-type="pmid">35989569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abou-Zeid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boursoulian</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Metzer</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Gundogdu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Morvan syndrome: a case report and review of the literature.</article-title>
            <source>J Clin Neuromuscul Dis</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>214</fpage>
            <page-range>214-27</page-range>
            <pub-id pub-id-type="pmid">22622167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagnall-Moreau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huerta</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Comoletti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>La-Bella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Volpe</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brimberg</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>In utero exposure to endogenous maternal polyclonal anti-Caspr2 antibody leads to behavioral abnormalities resembling autism spectrum disorder in male mice.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Sep</month>
            <day>02</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>14446</fpage>
            <pub-id pub-id-type="pmid">32879327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asbeutah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alhashime</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alhamer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Case Report and Literature Review on Positivity for Multiple Antibodies: Autoimmune Encephalitis in Focus.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e50393</fpage>
            <pub-id pub-id-type="pmid">38213350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Maselli</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Agius</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>857</fpage>
            <page-range>857-62</page-range>
            <pub-id pub-id-type="pmid">9854961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of limbic encephalitis with LGI1 antibody.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>1589</fpage>
            <page-range>1589-1596</page-range>
            <pub-id pub-id-type="pmid">28670128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Sonderen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rtv&#x000e9;lyessy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wandinger</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The clinical spectrum of Caspr2 antibody-associated disease.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Aug</month>
            <day>02</day>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>521</fpage>
            <page-range>521-8</page-range>
            <pub-id pub-id-type="pmid">27371488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poliak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gollan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Custer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Einheber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Salzer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Trimmer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shrager</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peles</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels.</article-title>
            <source>Neuron</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>1037</fpage>
            <page-range>1037-47</page-range>
            <pub-id pub-id-type="pmid">10624965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryding</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Blaabjerg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiological Effects of Autoantibodies in Autoimmune Encephalitides.</article-title>
            <source>Cells</source>
            <year>2023</year>
            <month>Dec</month>
            <day>20</day>
            <volume>13</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38201219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fels</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mayeur</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wayere</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malleval</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Dysregulation of the hippocampal neuronal network by LGI1 auto-antibodies.</article-title>
            <source>PLoS One</source>
            <year>2022</year>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>e0272277</fpage>
            <pub-id pub-id-type="pmid">35984846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramirez-Franco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Debreux</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Extremet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maulet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Belghazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sangiardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Youssouf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>El Far</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>L&#x000e9;v&#x000ea;que</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Debarnot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marchot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paneva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Debanne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Russier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seagar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>El Far</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Patient-derived antibodies reveal the subcellular distribution and heterogeneous interactome of LGI1.</article-title>
            <source>Brain</source>
            <year>2022</year>
            <month>Nov</month>
            <day>21</day>
            <volume>145</volume>
            <issue>11</issue>
            <fpage>3843</fpage>
            <page-range>3843-3858</page-range>
            <pub-id pub-id-type="pmid">35727946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ludewig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Salzburger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goihl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rohne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D&#x000fc;zel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schraven</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reinhold</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Korte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rtv&#x000e9;lyessy</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis.</article-title>
            <source>Cells</source>
            <year>2023</year>
            <month>Jan</month>
            <day>11</day>
            <volume>12</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36672216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Antibody-LGI 1 autoimmune encephalitis manifesting as rapidly progressive dementia and hyponatremia: a case report and literature review.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>07</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">30732585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gadoth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nisnboym</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alcalay</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zubkov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abboud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rubinek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yossepowitch</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Electrolyte Imbalance in Anti-LGI1 Encephalitis: It Is Not All in Your Head.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">37591767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Morvan's syndrome with anti contactin associated protein like 2 - voltage gated potassium channel antibody presenting with syndrome of inappropriate antidiuretic hormone secretion.</article-title>
            <source>J Neurosci Rural Pract</source>
            <year>2016</year>
            <season>Oct-Dec</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-579</page-range>
            <pub-id pub-id-type="pmid">27695240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Antibody-Mediated Encephalitis.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>378</volume>
            <issue>9</issue>
            <fpage>840</fpage>
            <page-range>840-851</page-range>
            <pub-id pub-id-type="pmid">29490181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Provini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Differentiating Oneiric Stupor in Agrypnia Excitata From Dreaming Disorders.</article-title>
            <source>Front Neurol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>565694</fpage>
            <pub-id pub-id-type="pmid">33281702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haug</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Schoenle</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Karch</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bardosi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holzgraefe</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Morvan's fibrillary chorea. A case with possible manganese poisoning.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>1989</year>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-9</page-range>
            <pub-id pub-id-type="pmid">2538282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lotan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Djaldetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hellman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Benninger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Atypical case of Morvan's syndrome.</article-title>
            <source>J Clin Neurosci</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>25</volume>
            <fpage>132</fpage>
            <page-range>132-4</page-range>
            <pub-id pub-id-type="pmid">26549678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clover</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Potassium channel antibodies in two patients with reversible limbic encephalitis.</article-title>
            <source>Ann Neurol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-8</page-range>
            <pub-id pub-id-type="pmid">11456313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takamiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shiojima</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Concurrence of myasthenia gravis and chor&#x000e9;e fibrillaire de Morvan.</article-title>
            <source>Eur Arch Psychiatry Neurol Sci</source>
            <year>1990</year>
            <volume>239</volume>
            <issue>5</issue>
            <fpage>335</fpage>
            <page-range>335-6</page-range>
            <pub-id pub-id-type="pmid">2140784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f6;mberg</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular, autonomic and central cholinergic hyperactivity associated with thymoma and acetylcholine receptor-binding antibody.</article-title>
            <source>J Neurol</source>
            <year>1987</year>
            <month>Aug</month>
            <volume>234</volume>
            <issue>6</issue>
            <fpage>433</fpage>
            <page-range>433-6</page-range>
            <pub-id pub-id-type="pmid">3655849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gardner-Medwin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Myokymia with impaired muscular relaxation.</article-title>
            <source>Lancet</source>
            <year>1969</year>
            <month>May</month>
            <day>03</day>
            <volume>1</volume>
            <issue>7601</issue>
            <fpage>943</fpage>
            <page-range>943-4</page-range>
            <pub-id pub-id-type="pmid">4180920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsili</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marcucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LaPorta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chirra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment.</article-title>
            <source>Biomedicines</source>
            <year>2023</year>
            <month>May</month>
            <day>09</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37239077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Wel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Claeys</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular hyperexcitability syndromes.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>714</fpage>
            <page-range>714-720</page-range>
            <pub-id pub-id-type="pmid">34914668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sleep Disturbances in Autoimmune Neurologic Diseases: Manifestation and Pathophysiology.</article-title>
            <source>Front Neurosci</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>687536</fpage>
            <pub-id pub-id-type="pmid">34421519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michael</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.</article-title>
            <source>Pract Neurol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>377</fpage>
            <page-range>377-384</page-range>
            <pub-id pub-id-type="pmid">32595134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Sleep Disorders in Leucine-Rich Glioma-Inactivated Protein 1 and Contactin Protein-Like 2 Antibody-Associated Diseases.</article-title>
            <source>Front Neurol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>696</fpage>
            <pub-id pub-id-type="pmid">32849186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumgartner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pitsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olaciregui-Dague</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Racz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000fc;ber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Wrede</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Surges</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Seizure underreporting in LGI1 and CASPR2 antibody encephalitis.</article-title>
            <source>Epilepsia</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>9</issue>
            <fpage>e100</fpage>
            <page-range>e100-e105</page-range>
            <pub-id pub-id-type="pmid">35735209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benedetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franciotta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zoccarato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beronio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schirinzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siciliano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ciarmiello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Del Sette</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Post-therapy normalization of brain FDG-PET in Morvan's syndrome.</article-title>
            <source>J Neurol Sci</source>
            <year>2015</year>
            <volume>353</volume>
            <issue>1-2</issue>
            <fpage>175</fpage>
            <page-range>175-6</page-range>
            <pub-id pub-id-type="pmid">25896288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nawfal</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Agha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Makki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beydoun</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Refractory Morvan syndrome responsive to rituximab: a case report and review of the literature.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>682</fpage>
            <page-range>682-686</page-range>
            <pub-id pub-id-type="pmid">35715317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sveinsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al Nimer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piehl</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Morvan's syndrome treated successfully with rituximab and lacosamide.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>13</day>
            <volume>12</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30765442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nonaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ebisu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shizukawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shimohama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Morvan syndrome associated with unresectable thymoma responsive to chemotherapy: a case report].</article-title>
            <source>Rinsho Shinkeigaku</source>
            <year>2022</year>
            <month>Aug</month>
            <day>27</day>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>615</fpage>
            <page-range>615-620</page-range>
            <pub-id pub-id-type="pmid">35871563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flanagan</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Geschwind</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lopez-Chiriboga</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Blackburn</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Turaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Binks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zitser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Dunham</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rodenbeck</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Clardy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zekeridou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toledano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Vernino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Encephalitis Misdiagnosis in Adults.</article-title>
            <source>JAMA Neurol</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-39</page-range>
            <pub-id pub-id-type="pmid">36441519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carozza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Functional Impairments in a Patient with Morvan Syndrome: A&#x000a0;Case Presentation.</article-title>
            <source>PM R</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>766</fpage>
            <page-range>766-769</page-range>
            <pub-id pub-id-type="pmid">29222073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vogrig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;iz-Castrillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Desestret</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giometto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Joubert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Psimaras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vedeler</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">34006622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;scher</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Wanschitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reiners</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quasthoff</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Morvan's syndrome: clinical, laboratory, and in vitro electrophysiological studies.</article-title>
            <source>Muscle Nerve</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-63</page-range>
            <pub-id pub-id-type="pmid">15266630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katirji</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Peripheral nerve hyperexcitability.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2019</year>
            <volume>161</volume>
            <fpage>281</fpage>
            <page-range>281-290</page-range>
            <pub-id pub-id-type="pmid">31307606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skolka</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Soontrapa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Litchy</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gardon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liewluck</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Immune-mediated rippling muscle disease: not your usual muscle twitches and ache.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-240</page-range>
            <pub-id pub-id-type="pmid">36745949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parr</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bashford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Facial myokymia as the presenting feature of multiple sclerosis.</article-title>
            <source>Pract Neurol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-234</page-range>
            <pub-id pub-id-type="pmid">34992095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bili&#x00107;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Adamec</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Focal platysma myokymia as the presenting symptom of cervical radiculopathy.</article-title>
            <source>Neurol Sci</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>2221</fpage>
            <page-range>2221-2222</page-range>
            <pub-id pub-id-type="pmid">36849694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esechie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shanina</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin-Induced Myokymia: A Case Report.</article-title>
            <source>Clin Neuropharmacol</source>
            <string-date>2021 Mar-Apr 01</string-date>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-76</page-range>
            <pub-id pub-id-type="pmid">33480615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alapatt</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Johny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>K P</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>V V</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide-Induced Periorbital Myokymia: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>e31920</fpage>
            <pub-id pub-id-type="pmid">36579233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liguori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clover</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Avoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Plazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baruzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels.</article-title>
            <source>Brain</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>124</volume>
            <issue>Pt 12</issue>
            <fpage>2417</fpage>
            <page-range>2417-26</page-range>
            <pub-id pub-id-type="pmid">11701596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Provini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications.</article-title>
            <source>Auton Neurosci</source>
            <year>2019</year>
            <month>May</month>
            <volume>218</volume>
            <fpage>68</fpage>
            <page-range>68-86</page-range>
            <pub-id pub-id-type="pmid">30890351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Britton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gadoth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zekeridou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lopez Chiriboga</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sagen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.</article-title>
            <source>Ann Neurol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-323</page-range>
            <pub-id pub-id-type="pmid">31782181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41210.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anesthetic management of patients with Morvan syndrome - A rare disorder.</article-title>
            <source>Saudi J Anaesth</source>
            <year>2023</year>
            <season>Apr-Jun</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-302</page-range>
            <pub-id pub-id-type="pmid">37260662</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
